A Comparative Computational Study of Dipeptidyl Peptidase‐IV (DPP‐IV) Inhibitor Sets as Antidiabetic Agents: Molecular Dynamics, Binding Affinity, and Drug‐Likeness (ADMET)
Abstract
This work systematically investigates nine structurally different DPP‐IV inhibitors co‐crystallized in PDB complexes (2JID, 2OAG, 2OGZ, 2OLE, 2P8S, 2RGU, 3BJM, 3C43, 3D4L) as therapeutic target for Type 2 Diabetes Mellitus, using all‐atom molecular dynamics (MD) simulations (300 ns) and MM/GBSA free energy calculations. Results revealed the ionic interaction with the Glu205‐Glu206 dyad as the universal anchoring motif, which is present in all stable complexes with 100% occupancy. Linagliptin (2RGU) as xanthine‐based inhibitor showed superior kinetic stability, verified by low ligand RMSD (∼0.8 Å), minimal distance fluctuation from the catalytic Ser630, and a high number of persistent water‐bridged hydrogen bonds. On the other hand, inhibitors like the 2P8S analog, although their promising MM/GBSA score (−56.74 kcal/mol), experienced late‐stage dissociation, demonstrating the limitation of static or purely thermodynamic assessments. Ligand rigidity, the existence of special anchoring interactions (such as π‐stacking with Trp629 in 2RGU), and the quality rather than just quantity of hydrophobic contacts in the S1/S2 extended pockets were important stability differentiators. Simultaneously, ADMET profiling showed that although the majority of drugs follow Lipinski's rule of five and have good gastrointestinal absorption, a few ones have serious drawbacks, such as poor water solubility, CYP450 inhibition, and PAINS/Brenk alarms.